Cargando…

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

Background and objectives: Demand for assisted reproduction technology (ART) in Germany is high, with 100,844 treatment cycles during 2016. Many ART procedures involve ovarian stimulation with follicle stimulating hormone (FSH). Recently, biosimilar FSH products have become available. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Weiguang, Lloyd, Adam, Falla, Edel, Roeder, Claudia, Papsch, Rudiger, Bühler, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524790/ https://www.ncbi.nlm.nih.gov/pubmed/31191040 http://dx.doi.org/10.2147/IJWH.S193048

Ejemplares similares

A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
por: Gizzo, Salvatore, et al.
Publicado: (2016)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
por: Patel, Nayana Hitesh, et al.
Publicado: (2023)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023)

Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
por: Riccetti, Laura, et al.
Publicado: (2019)

Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
por: Manzi, Lucio, et al.
Publicado: (2022)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
por: Bühler, Klaus
Publicado: (2015)

Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting
por: Griesinger, Georg, et al.
Publicado: (2021)

A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
por: Bühler, Klaus, et al.
Publicado: (2014)

Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Chua, Su Jen, et al.
Publicado: (2021)

Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Venetis, Christos A., et al.
Publicado: (2023)

A Novel Follitropin Analog Inhibits Follitropin Activity In Vitro
por: Azzam, Naiel, et al.
Publicado: (2021)

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2020)

Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT
por: Hossein Rashidi, Batool, et al.
Publicado: (2021)

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2021)

A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study
por: Bühler, Klaus, et al.
Publicado: (2011)

In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta
por: Haakman, Olga, et al.
Publicado: (2020)

Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study
por: Doroftei, Bogdan, et al.
Publicado: (2021)

Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
por: Welcker, J Thomas, et al.
Publicado: (2010)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
por: Kaplan, Sigal, et al.
Publicado: (2021)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany
por: Blankart, Katharina E., et al.
Publicado: (2020)

Comparison of follitropin β administered by a pen device with follitropin β administered by a conventional syringe in patients undergoing IVF-ET
por: Kang, Hyuk-Jae, et al.
Publicado: (2011)

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency
por: Rinaldi, Leonardo, et al.
Publicado: (2016)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes
por: Doroftei, Bogdan, et al.
Publicado: (2023)

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland
por: Carl, David L., et al.
Publicado: (2022)

Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment
por: Illingworth, Peter J, et al.
Publicado: (2014)

Biosimilar medicines and cost-effectiveness
por: Simoens, Steven
Publicado: (2011)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Ovulation induction with minimal dose of follitropin alfa: a case series study
por: Bruna-Catalán, Isidoro, et al.
Publicado: (2011)

In Vitro Effects of the Endocrine Disruptor p,p’-DDT on Human Follitropin Receptor
por: Munier, Mathilde, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women
por: Shao, Feng, et al.
Publicado: (2022)

The Effect of Follitropin Alfa in Controlled Ovarian Stimulation Protocol for In Vitro Fertilization Cycles
por: Prasetiawati, Novita, et al.
Publicado: (2023)

Human factors engineering and design validation for the redesigned follitropin alfa pen injection device
por: Mahony, Mary C, et al.
Publicado: (2015)

An Economic Analysis of Aneuploidy Screening of Oocytes in Assisted Reproduction in Germany
por: Neumann, Kay, et al.
Publicado: (2020)

Who can take advantage of medically assisted reproduction in Germany?
por: Köppen, Katja, et al.
Publicado: (2021)

Biosimilars: new promise for reducing healthcare costs
por: Munsch, Julia
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7dnd5ijltnbbkemgfka63jfpa0